Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070243316> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2070243316 endingPage "755" @default.
- W2070243316 startingPage "753" @default.
- W2070243316 abstract "The Hepatitis B e antigen (HBeAg) is a non-particulate secretory protein, which is not essential for viral assembly or replication but is important for the establishment of persistent infection in vivo. A recent study suggested that it down-regulates the innate immune response to infection and function as a T cell tolerogen [1]. For patients with chronic HBeAg positive chronic hepatitis B infection (CHB), HBeAg seroconversion, defined as loss of HBeAg with the appearance of anti-HBe, is often associated with clinical remission and a transition to inactive liver disease [2]. Accompanying HBeAg seroconversion, there is a reduction in liver fibrosis, a lower incidence of cirrhosis and hepatocellular carcinoma. HBeAg seroconversion, whether spontaneous or treatment-induced, is also associated with a higher probability of hepatitis B surface antigen (HBsAg) loss and seroconversion, which is considered to be a more permanent clinical remission of liver disease. Thus, the achievement and maintenance of HBeAg seroconversion, in association with polymerase chain reactionundetectable hepatitis B virus (HBV) DNA levels, are an important goal in the management of patients with HBeAg-positive CHB. Based on evidence demonstrating HBeAg seroconversion as an important hallmark event of a durable clinical remission of liver disease, major liver societies treatment guidelines have adopted HBeAg seroconversion with sustained suppression of HBV DNA as an end point for treatment in patients with HBeAg-positive CHB who do not have cirrhosis or decompensated liver disease. To date, there are seven registered treatments for CHB, two immunomodulatory agents – conventional interferon-a and pegylated interferon a2a – and five nucleos(t)ide analogues (NUCs) – lamivudine, adefovir dipivoxil, telbivudine, entecavir, and tenofovir dipropoxil. Among the various forms of treatment, one-year treatment with pegylated interferon a2a yielded the highest rate of HBeAg seroconversion (around 40%) and among them, one-tenth further benefit from HBsAg seroconversion. On the other hand, treatment with NUCs achieved a much lower rate" @default.
- W2070243316 created "2016-06-24" @default.
- W2070243316 creator A5042037558 @default.
- W2070243316 creator A5051162009 @default.
- W2070243316 date "2012-04-01" @default.
- W2070243316 modified "2023-09-23" @default.
- W2070243316 title "Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: A need for more translational study" @default.
- W2070243316 cites W1856316812 @default.
- W2070243316 cites W1976643312 @default.
- W2070243316 cites W1984684294 @default.
- W2070243316 cites W2008583523 @default.
- W2070243316 cites W2035424287 @default.
- W2070243316 cites W2036627386 @default.
- W2070243316 cites W2037206310 @default.
- W2070243316 cites W2076723714 @default.
- W2070243316 doi "https://doi.org/10.1016/j.jhep.2011.12.006" @default.
- W2070243316 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22230868" @default.
- W2070243316 hasPublicationYear "2012" @default.
- W2070243316 type Work @default.
- W2070243316 sameAs 2070243316 @default.
- W2070243316 citedByCount "15" @default.
- W2070243316 countsByYear W20702433162013 @default.
- W2070243316 countsByYear W20702433162014 @default.
- W2070243316 countsByYear W20702433162015 @default.
- W2070243316 countsByYear W20702433162017 @default.
- W2070243316 countsByYear W20702433162020 @default.
- W2070243316 countsByYear W20702433162021 @default.
- W2070243316 crossrefType "journal-article" @default.
- W2070243316 hasAuthorship W2070243316A5042037558 @default.
- W2070243316 hasAuthorship W2070243316A5051162009 @default.
- W2070243316 hasBestOaLocation W20702433161 @default.
- W2070243316 hasConcept C147483822 @default.
- W2070243316 hasConcept C159047783 @default.
- W2070243316 hasConcept C159654299 @default.
- W2070243316 hasConcept C203014093 @default.
- W2070243316 hasConcept C2522874641 @default.
- W2070243316 hasConcept C2775940106 @default.
- W2070243316 hasConcept C2777410769 @default.
- W2070243316 hasConcept C2777451964 @default.
- W2070243316 hasConcept C2780593183 @default.
- W2070243316 hasConcept C71924100 @default.
- W2070243316 hasConcept C8891405 @default.
- W2070243316 hasConceptScore W2070243316C147483822 @default.
- W2070243316 hasConceptScore W2070243316C159047783 @default.
- W2070243316 hasConceptScore W2070243316C159654299 @default.
- W2070243316 hasConceptScore W2070243316C203014093 @default.
- W2070243316 hasConceptScore W2070243316C2522874641 @default.
- W2070243316 hasConceptScore W2070243316C2775940106 @default.
- W2070243316 hasConceptScore W2070243316C2777410769 @default.
- W2070243316 hasConceptScore W2070243316C2777451964 @default.
- W2070243316 hasConceptScore W2070243316C2780593183 @default.
- W2070243316 hasConceptScore W2070243316C71924100 @default.
- W2070243316 hasConceptScore W2070243316C8891405 @default.
- W2070243316 hasIssue "4" @default.
- W2070243316 hasLocation W20702433161 @default.
- W2070243316 hasLocation W20702433162 @default.
- W2070243316 hasOpenAccess W2070243316 @default.
- W2070243316 hasPrimaryLocation W20702433161 @default.
- W2070243316 hasRelatedWork W1965759593 @default.
- W2070243316 hasRelatedWork W1977907407 @default.
- W2070243316 hasRelatedWork W1990481071 @default.
- W2070243316 hasRelatedWork W1992896253 @default.
- W2070243316 hasRelatedWork W2007609529 @default.
- W2070243316 hasRelatedWork W2017544623 @default.
- W2070243316 hasRelatedWork W2081817726 @default.
- W2070243316 hasRelatedWork W2092592271 @default.
- W2070243316 hasRelatedWork W2220102944 @default.
- W2070243316 hasRelatedWork W2962651724 @default.
- W2070243316 hasVolume "56" @default.
- W2070243316 isParatext "false" @default.
- W2070243316 isRetracted "false" @default.
- W2070243316 magId "2070243316" @default.
- W2070243316 workType "article" @default.